Cognex Corporation 10-K Summary: Fiscal Year Ended December 31, 1999
Business Context and Reporting Period
Cognex Corporation (Cognex) is a leading worldwide supplier of machine vision systems used to automate manufacturing processes. The company designs, develops, and markets systems consisting of a "machine vision engine" (computer) and software that processes images to guide, identify, inspect, and gauge objects. The reporting period covers the fiscal year ended December 31, 1999. Cognex serves two primary customer types: Original Equipment Manufacturers (OEMs) and end users across industries such as semiconductor, electronics, automotive, and consumer products.
Key Financial Metrics
Revenue and Expenses: The filing text does not provide the total revenue figure for 1999, as the Consolidated Statements of Income are incorporated by reference from the Annual Report to Stockholders (Exhibit 13). However, Research, Development, and Engineering (R, D & E) expenses were $27,669,000, representing 18% of revenue.
Backlog: Total backlog at December 31, 1999, was $36,788,000, compared to $17,216,000 at December 31, 1998.
Market Capitalization: The aggregate market value of voting stock held by non-affiliates as of February 27, 2000, was approximately $1.91 billion. There were 42,542,247 shares of common stock outstanding as of that date.
Valuation Accounts (in thousands):
- Allowance for Doubtful Accounts: Ending balance of $2,836 (up from $2,583 in 1998).
- Reserve for Inventory Obsolescence: Ending balance of $3,955 (up from $2,860 in 1998).
Liquidity and Investments: The company maintains an investment portfolio of cash equivalents and available-for-sale securities. The carrying amounts of cash, trade receivables, and trade payables approximate fair value due to short maturities. The company does not currently hedge interest rate exposures.
Material Changes and Trends
- Backlog Growth: Backlog more than doubled from $17.2 million in 1998 to $36.8 million in 1999, indicating strong order intake, though the company notes this is not necessarily indicative of future revenue.
- R&D Investment: R&D expenses increased to $27.7 million (18% of revenue) in 1999, up from $24.7 million (20% of revenue) in 1998 and $22.5 million (14% of revenue) in 1997.
- International Sales: Sales to international customers represented approximately 69% of revenue in 1999, an increase from 63% in 1998 and 62% in 1997.
- Customer Concentration: One customer, Fuji America Corporation (Japan), accounted for approximately 13% of revenue in 1999, down from 14% in 1998 and 18% in 1997.
- Product Launches: In early 2000, the company introduced the In-Sight 2000, a low-cost vision sensor, and the PatFind tool, expanding its reach into the end-user market.
Outlook, Risks, and Contingencies
Guidance and Outlook: The company intends to continue investing in direct sales and support infrastructure globally and expanding into new industrial machine vision applications through internal development and acquisitions. Management emphasizes high value-added products and applications.
Legal Proceedings: The company is involved in litigation with the Lemelson Medical, Educational, & Research Foundation, Limited Partnership ("Partnership"). The Partnership alleges that users of Cognex products infringe certain patents. Cognex filed a declaratory judgment action in September 1998 (refiled in Nevada in September 1999) seeking a declaration that the patents are invalid and not infringed. The outcome is uncertain and could take several years to resolve.
Market Risks:
- Currency Risk: The company faces exposure to foreign currency exchange rates, particularly in Japan, Europe, and Southeast Asia. As of February 18, 2000, indicators suggested a strengthening dollar against the yen, with a hypothetical gain of $2.3 million on outstanding yen forward contracts.
- Interest Rate Risk: The company holds an investment portfolio sensitive to interest rate changes. A hypothetical 100 basis point increase in interest rates would decrease the fair value of municipal obligations by approximately $4.5 million (from $202.9 million to $198.3 million).
Dividends: The company has never declared or paid cash dividends and intends to retain earnings to finance business development.
Key Facts for Investor Verification
- Revenue Figures: Verify total revenue, net income, and cash flow figures in the Consolidated Statements of Income and Cash Flows (Exhibit 13), as these specific numbers are not explicitly stated in the 10-K text provided.
- Backlog Conversion: Monitor the conversion rate of the $36.8 million backlog into actual revenue, noting the company's disclaimer that backlog is not necessarily indicative of future revenue.
- Lemelson Litigation: Track the status of the patent infringement lawsuit against the Lemelson Partnership, as a negative outcome could result in indemnification claims from customers or restrictions on product sales.
- Customer Concentration: Assess the risk associated with Fuji America Corporation, which still represents a significant portion (13%) of revenue despite a declining trend.
- Product Adoption: Evaluate the market reception of the new In-Sight 2000 product line, which is critical to the company's strategy of expanding into the end-user market.